MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MYOK
- Previous Close: $12.25
- 50 Day Moving Average: $12.34
- 200 Day Moving Average: $15.77
- 52-Week Range: $6.87 - $22.83
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.31
- P/E Growth: 0.00
- Market Cap: $384.99M
- Outstanding Shares: 31,428,000
- Beta: 6.53
- Net Margins: -248.75%
- Return on Equity: -43.41%
- Return on Assets: -35.87%
Companies Related to MyoKardia:
- Current Ratio: 6.38%
- Quick Ratio: 6.38%
What is MyoKardia's stock symbol?
MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."
Where is MyoKardia's stock going? Where will MyoKardia's stock price be in 2017?
5 brokerages have issued 1 year price targets for MyoKardia's stock. Their predictions range from $20.00 to $28.00. On average, they expect MyoKardia's share price to reach $25.00 in the next twelve months.
When will MyoKardia announce their earnings?
MyoKardia is scheduled to release their next quarterly earnings announcement on Thursday, March, 16th 2017.
Who owns MyoKardia stock?
MyoKardia's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (12.38%), Perceptive Advisors LLC (1.99%), Deerfield Management Co. (1.35%), State Street Corp (0.57%), Marshall Wace LLP (0.39%) and Harbourvest Partners LLC (0.14%). Company insiders that own MyoKardia stock include Anastasios Gianakakos, Jonathan C Fox, Mark L Perry and Sanofi.
Who sold MyoKardia stock? Who is selling MyoKardia stock?
MyoKardia's stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co..
Who bought MyoKardia stock? Who is buying MyoKardia stock?
MyoKardia's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Harbourvest Partners LLC, State Street Corp, Marshall Wace LLP, Trexquant Investment LP, A.R.T. Advisors LLC, Aberdeen Asset Management PLC UK and Bessemer Group Inc.. Company insiders that have bought MyoKardia stock in the last two years include Anastasios Gianakakos, Jonathan C Fox, Mark L Perry and Sanofi.
How do I buy MyoKardia stock?
Shares of MyoKardia can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MyoKardia stock cost?
One share of MyoKardia stock can currently be purchased for approximately $12.20.